Song Xiang, Hu Weiyu, Zhang Li, Mao Tao, Zhu Yingli, Chen Xiaokai, Ren Linlin
Department of Gastroenterology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Front Oncol. 2025 Apr 29;15:1563729. doi: 10.3389/fonc.2025.1563729. eCollection 2025.
Pancreatic lymphoma is a rare pancreatic malignancy that is challenging to differentiate from diseases such as pancreatic cancer (PC). Although pathological examination of specimens obtained through surgery or endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) can aid in diagnosis, factors such as the occasional need for surgery and the variability in specimen quality from EUS-FNA complicate the diagnostic process. Misdiagnosis of pancreatic lymphoma as PC often leads to unnecessary surgery. In addition, surgical intervention may be necessary as a second-line treatment option for pancreatic lymphoma patients presenting with severe gastrointestinal symptoms. However, an optimal postoperative treatment strategy remains undefined, particularly in cases with extensive invasion, thereby impacting long-term survival. This lack of consensus underscores the need for further research to establish evidence-based therapeutic protocols.
We present the case of a 55-year-old patient (abdominal pain for over one month, intensified for two weeks). Imaging studies suggested a hypodense mass in the tail of the pancreas with ill-defined margins extending to the spleen, as well as a hypodense lesion within the spleen. The patient underwent surgical intervention, and postoperative pathological analysis confirmed the diagnosis of diffuse large B-cell lymphoma (DLBCL). Following surgery, the patient was initially treated with a short-term C2PET oral chemotherapy regimen, which was subsequently transitioned to the R-CHOP regimen. This therapeutic approach resulted in a favorable outcome, with the patient achieving a 5-year survival period. As far as we know, this may be the first reported case of pancreatic lymphoma with such a widespread involvement, in which patient underwent surgery and postoperative chemotherapy and obtained a 5-year survival period.
We reviewed previously reported cases of the DLBCL pancreatic lymphoma located in the body and tail of pancreas, and conducted a comparative analysis.
Our objectives are twofold: first, to highlight the critical role of preoperative EUS-FNA and positron emission tomography-computed tomography in the diagnostic evaluation for patients with pancreatic mass and suspected lesions in immune-associated organs; and second, to propose evidence-based recommendations for postoperative chemotherapy in cases of DLBCL involving the pancreas.
胰腺淋巴瘤是一种罕见的胰腺恶性肿瘤,很难与胰腺癌(PC)等疾病区分开来。尽管通过手术或内镜超声引导下细针穿刺活检(EUS-FNA)获取标本进行病理检查有助于诊断,但诸如偶尔需要手术以及EUS-FNA获取的标本质量存在差异等因素使诊断过程变得复杂。将胰腺淋巴瘤误诊为PC往往会导致不必要的手术。此外,对于出现严重胃肠道症状的胰腺淋巴瘤患者,手术干预可能作为二线治疗选择是必要的。然而,最佳的术后治疗策略仍不明确,尤其是在广泛侵犯的病例中,从而影响长期生存。这种缺乏共识凸显了进一步研究以建立循证治疗方案的必要性。
我们报告一例55岁患者(腹痛一个多月,加重两周)。影像学检查提示胰腺尾部有一低密度肿块,边界不清,延伸至脾脏,脾脏内还有一低密度病变。患者接受了手术干预,术后病理分析确诊为弥漫性大B细胞淋巴瘤(DLBCL)。手术后,患者最初接受了短期C2PET口服化疗方案,随后转为R-CHOP方案。这种治疗方法取得了良好的效果,患者实现了5年生存期。据我们所知,这可能是首例报道的胰腺淋巴瘤广泛累及的病例,该患者接受了手术及术后化疗并获得了5年生存期。
我们回顾了先前报道的位于胰体尾的DLBCL胰腺淋巴瘤病例,并进行了对比分析。
我们的目标有两个:第一,强调术前EUS-FNA和正电子发射断层扫描-计算机断层扫描在胰腺肿块及免疫相关器官疑似病变患者诊断评估中的关键作用;第二,为累及胰腺的DLBCL病例的术后化疗提出循证建议。